• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Core Scientific (CORZ) Heads To Investor Conference, Is The 57% Undervaluation Convincing?

    Simply Wall St·09/16/2026 18:25:35
    语音播报

    Core Scientific (CORZ) is heading into the H.C. Wainwright 28th Annual Global Investment Conference on 14 September 2026, where Chief Development Officer Russell Cann is scheduled to outline the business to prospective investors.

    In the run-up to the conference, Core Scientific’s share price has been under pressure, with a 7-day share price return down 14.36% and a 90-day share price return down 43.48%. Short-term momentum has faded even though the year-to-date share price return is roughly flat and the 1-year total shareholder return is slightly negative.

    Compare Core Scientific’s recent slide with a curated group of beaten-down opportunities using the 34 high quality undervalued stocks as a starting watchlist.

    Core Scientific now splits opinion. Bulls point to rapid revenue and net income growth, while bears focus on the share price slide and ongoing losses. Which reading lines up with the current valuation?

    Most Popular Narrative: 57% Undervalued

    Core Scientific closed at $16.04, while the most followed narrative pegs fair value at $37.13. The gap between price and story is wide and very clear heading into the conference.

    Core Scientific secured a major HPC contract with CoreWeave, with a total revenue potential of $8.7 billion over a 12-year term, significantly boosting future revenue compared to their current levels. The company is expanding HPC infrastructure capacity by reallocating resources from Bitcoin mining, adding new sites, and extending existing ones, expecting to drive future revenue growth as data center needs rise.

    See why 60 investors see Core Scientific as 57% undervalued.

    Result: Fair Value of $37.13 (UNDERVALUED)

    Still, the narrative around Core Scientific can crack quickly if execution on new high performance compute capacity slips or if CoreWeave’s demand and commitments soften.

    Find out about the key risks to this Core Scientific narrative.

    Another View: Core Scientific Looks Expensive On Sales

    The first story around Core Scientific leans heavily on analyst fair value and long dated AI contracts. A simple P/S check paints a very different picture.

    At roughly 11.7x P/S, Core Scientific trades at about 3x the US Software industry average of 3.9x and around 4x the peer group on 2.9x. The fair ratio estimate sits closer to 6x, which suggests valuation risk if expectations cool. How comfortable are you paying that kind of premium for growth that still needs to be delivered?

    See what the numbers say about this price — find out in our valuation breakdown.

    NasdaqGS:CORZ P/S Ratio as at Sep 2026
    NasdaqGS:CORZ P/S Ratio as at Sep 2026

    Next Steps

    Mixed messages around Core Scientific’s value can easily pull you in different directions, so move quickly through the numbers and pressure test the story for yourself. To see how the potential upside compares with the key concerns in one place, check out the 1 key reward and 3 important warning signs

    Looking for more Core Scientific sized ideas?

    If Core Scientific has caught your attention, do not stop at one ticker. Use screeners to spot other opportunities before the broader market catches on.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.